Company news

Ipsen SA news in 2026

Ipsen SA's news releases, calls and decks from 2026, newest first.

View company

Ipsen - April 2026- Monthly information relative to the total number of voting rights and shares composing the share capital

May 18, 2026

Ipsen initiates a new share buy-back program

May 18, 2026

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

May 16, 2026

Late-breaking data from EASL reinforces IQIRVO’s impact on ALP reduction with fatigue and pruritus improvement in patients with PBC

May 15, 2026

Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the SCALE Symposium

May 14, 2026

Ipsen S.A. – Evolution of the composition of the Board of Directors

May 13, 2026

Annual General Meeting of Ipsen S.A. held on 13 May 2026

May 13, 2026

Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance

April 23, 2026

Ipsen S.A. - Information relating to the holding of the Combined Shareholders’ Meeting of 13 May 2026

April 22, 2026

Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration

April 22, 2026

Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer

April 3, 2026

Ipsen announces the availability of its 2025 Universal Registration Document

April 1, 2026

Ipsen provides clarifications regarding the succession of Mr. Henri Beaufour – Group governance agreement relating to Beech Tree*

March 23, 2026

Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR

March 18, 2026

Ipsen - February 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital

March 13, 2026

Ipsen appoints Michelle C. Werner as EVP, President of North America

March 12, 2026

Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma

March 9, 2026

Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma

March 9, 2026

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma

February 27, 2026

Quotient Sciences Extends Commercial Manufacturing Partnership for Ultra-Rare Disease Treatment

February 26, 2026

Ellucian CEO Laura Ipsen Named 2026 CNBC Changemaker

February 25, 2026

GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales

February 12, 2026

Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance

February 12, 2026

Ipsen - January 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital

February 9, 2026

Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program

January 30, 2026

Ipsen nominates Peter Guenter to its Board of Directors

January 29, 2026

Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team

January 27, 2026

Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma

January 21, 2026

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

January 14, 2026

U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia

January 13, 2026

Ipsen - December 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

January 7, 2026

Ipsen – Half year statement – 2025 12 31

January 6, 2026

← Newer news releases

Calls in 2026

Decks in 2026